<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03239756</url>
  </required_header>
  <id_info>
    <org_study_id>Tmab-TK006-102</org_study_id>
    <nct_id>NCT03239756</nct_id>
  </id_info>
  <brief_title>Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases</brief_title>
  <official_title>Phase 1 Trial of a Fully Human Monoclonal Antibody of Receptor Activator for Nuclear Factor-κ B Ligand (RNAKL, TK006) Safety, Pharmacokinetics, and Pharmacodynamics in Patients With Breast Cancer-related Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu T-Mab Biopharma Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu T-Mab Biopharma Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, dose-escalating study to evaluate the safety,
      pharmacokinetics, immunogenicity, and preliminary efficacy of single and multiple
      subcutaneous injection TK006 in patients with breast cancer-related bone metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an single-center, open-label, dose-escalating study to evaluate the safety,
      pharmacokinetics, immunogenicity, and preliminary efficacy of single and multiple
      subcutaneous injection TK006 in patients with breast cancer-related bone metastases. It
      contains 4 cohorts：60 mg single-dose conhort, 120 mg single-dose conhort, 180 mg single-dose
      conhort and 120 mg Q4W （one dose every 4 weeks, 3 dose totally） conhort.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events (AEs) and serious adverse events (SAEs) which are related to TK006 assessed by CTCAE v4.03</measure>
    <time_frame>single dose cohort：112 days, multiple dose cohort：140 days</time_frame>
    <description>Collect the information of AEs and SAEs, vital sign, physical examination, laboratory examination and electrocardiogram during the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time 'last' where last is the last time point after administration [AUClast]</measure>
    <time_frame>single dose cohort：112 days, multiple dose cohort：140 days</time_frame>
    <description>Calculated by the linear trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity [AUC0-inf]</measure>
    <time_frame>single dose cohort：112 days, multiple dose cohort：140 days</time_frame>
    <description>Calculated by the linear trapezoidal and extrapolation method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed maximum plasma concentration [Cmax]</measure>
    <time_frame>single dose cohort：112 days, multiple dose cohort：140 days</time_frame>
    <description>The maximum (or peak) serum concentration that TK006 achieves after the drug has been administrated and before the administration of a second dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum observed plasma concentration [Tmax]</measure>
    <time_frame>single dose cohort：112 days, multiple dose cohort：140 days</time_frame>
    <description>The time at which the Cmax is observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life[T1/2]</measure>
    <time_frame>single dose cohort：112 days, multiple dose cohort：140 days</time_frame>
    <description>The time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bioavailability corrected apparent volume of the central compartment cleared of drug per unit [Cl/F]</measure>
    <time_frame>single dose cohort：112 days, multiple dose cohort：140 days</time_frame>
    <description>The apparent volume of the central compartment cleared of drug per unit time was estimated using the formula: Cl/F = Dose / AUC0-∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bioavailability corrected apparent volume of distribution [Vd/F]</measure>
    <time_frame>single dose cohort：112 days, multiple dose cohort：140 days</time_frame>
    <description>Apparent volume of distribution based on the terminal elimination phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine creatinine corrected cross-linked N-telopeptides of type I collagen [uNTX/Cr]</measure>
    <time_frame>single dose cohort：112 days, multiple dose cohort：140 days</time_frame>
    <description>For singel dose cohort, detecting the level of uNTX at screening period, day 0 (before dosing)、day 1, day 7, day 14, day 28, day 56, day 84 and day 112 For multiple dose cohort：detecting the level of uNTX at screening period, day 0 (before dosing)、day 1, day 7, day 14, day 28 (before dosing), day 56 (before dosing), day 84 and day 140.
Assessing the change of uNTX level to baseline and the uNTX should be corrected by urine creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum bone alkaline phosphatase [bALP]</measure>
    <time_frame>single dose cohort：112 days, multiple dose cohort：140 days</time_frame>
    <description>Assessing the change of serum bALP level to baseline. For singel dose cohort, detecting the level of uNTX at screening period, day 0 (before dosing)、day 1, day 7, day 14, day 28, day 56, day 84 and day 112 For multiple dose cohort：detecting the level of uNTX at screening period, day 0 (before dosing)、day 1, day 7, day 14, day 28 (before dosing), day 56 (before dosing), day 84 and day 140.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-drug antibody [ADA]</measure>
    <time_frame>single dose cohort：112 days, multiple dose cohort：140 days</time_frame>
    <description>Quantitative assay the ADA. For single cohort, the ADA titer would be detected at day 0 (before dosing) and day 56.
For multiple dose cohort, the ADA titer would be detected at day 0 (before dosing), day 28 (before dosing), day 56 (before dosing), day 84 and day 140.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>60 mg single dose cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients would receive a 60 mg single dose of TK006.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 mg single dose cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients would receive a 120 mg single dose of TK006.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 mg single dose cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients would receive a 180 mg single dose of TK006.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 mg Q4W cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients would receive 120 mg TK006 every 4 weeks, for a total of 3 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TK006</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>60 mg single dose cohort</arm_group_label>
    <arm_group_label>120 mg single dose cohort</arm_group_label>
    <arm_group_label>180 mg single dose cohort</arm_group_label>
    <arm_group_label>120 mg Q4W cohort</arm_group_label>
    <other_name>fully human monoclonal anti-RANKL antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients provide written informed consent voluntarily；

          2. 18~65 years old；

          3. Patients with pathology confirmed breast cancer radiological evidence with bone
             metastasis；

          4. Eastern Cooperative Oncology Group(ECOG) performance status≤2

          5. Anticipated life span≥6-month；

          6. Adequate reservation of hematopoiesis, liver and kidney functions:

               -  Absolute neutrophil count (ANC) ≥1.5×10^9/L

               -  Absolute platelet count (PLT) ≥100×10^9/L

               -  Hemoglobin (Hb) ≥90 g/L

               -  Total bilirubin (TBIL) ≤1.0 time the upper limit of normal (ULN)

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.0 ULN

               -  Serum creatinine (sCr) ≤2.0 ULN

          7. Albumin-adjusted calcium≥2.0 mmol/L, ≤2.9 mmol/ L(Calcium supplements are not allowed
             within 8 hours before examination).

        Exclusion Criteria:

          1. Hypersensitivity to any investigational medicine or supplements in this study.

          2. Women in Pregnancy or nursing.

          3. Anti-human immunodeficiency virus (HIV) antibody positive.

          4. Patients with hepatitis B virus DNA ≥10^5 copies/mL or active hepatitis C would not be
             selected. Stable hepatitis B or hepatitis C defined as AST/ALT≤2 ULN will not be
             selected as well if patients are not treated with antiviral therapy while receving
             immunosuppressive therapy or chemotherapy meanwhile.

          5. Prior malignancies (excluding the targeted breast cancer, basal cell carcinoma, or
             cervical cancer in situ) within 3 years.

          6. Uncontrolled systemic diseases, or organic or mental disorders that could affect
             compliance.

          7. Central nervous system metastasis that is symptomatic or require treatment.

          8. Unresolved toxicities ≥2 grades from previous chemo-therapy (excluding alopecia).

          9. Major surgery of bone or trauma within 4 weeks before the first dosing.

         10. Fracture of long bone within 90-day before the first dosing.

         11. Radiation therapy to bone within 2 weeks or treatment with radioisotopes within 8
             weeks before the first dosing.

         12. Treatment with diphosphonate within 30-day or administration of calcitonin,
             parathyroid hormone-related peptides, mithramycin, gallium nitrate or strontium
             ranelate within 6-month before the first dosing. Plan to receive systemic treatment
             with glucocorticosteroids over a long period during the trial.

         13. Hyperthyroidism or hypothyroidism, unless hypothyroidism patients are receiving
             regular treatment with thyroid hormone and:

        1) Thyroid stimulating hormone (TSH) is normal, or 2) TSH＞4.78μIU/Ml, ≤10.0μIU/mL and
        thyroxine (T4) is normal. 14. Disorders of hypoparathyroidism or hyperparathyroidism,
        osteomalacia, rheumatoid arthritis, acute attack of osteoarthritis, gout, Paget's disease,
        malabsorption syndrome, ascites, or other diseases that could affect bone metabolism.

        15. Previous or existing osteomyelitis or osteonecrosis of jaw, odontia or jaw diseases
        which are in active or require invasive operations, unhealing wound of oral surgery, or
        planned invasive dental operations during this trial.

        16. Has been selected for the study of other test devices or test drugs, or the duration of
        the clinical studies that have taken less than 30 days or 5 half-lives or biological
        effects, whichever is longer.

        17. Other situations which are not suitable for participation judged by the principal
        investigator (PI).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiang H Y</last_name>
    <role>Study Director</role>
    <affiliation>Jiangsu T-Mab Biopharma Co.,Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu M X</last_name>
    <phone>15021830072</phone>
    <email>yumingxia@sh-qingfeng.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiang H B</last_name>
    <phone>13062892252</phone>
    <email>jianghaibiao@sh-qingfeng.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the first affiliated hospital with Nanjing University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin Y M</last_name>
      <phone>13951842727</phone>
      <email>ym.yin@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2017</study_first_submitted>
  <study_first_submitted_qc>August 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2017</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

